Differential expression of Vegfr-2 and its soluble form in preeclampsia

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Munaut, Carine ^a   Lorquet, Sophie ^a,b   Pequeux, Christel ^a   Coulon, Capucine ^c   Le Goarant, Jeanne ^c   Chantraine, Frédéric ^a,b   Noël, Agnès ^a   Goffin, Frédéric ^b   Tsatsaris, Vassilis ^d   Subtil, Damien ^c   Foidart, Jean Michel ^a,b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b Centre Hospitalier Regional de La Citadelle   (Belgium)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d Institut Cochin   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOGLIN; MESSENGER RNA; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; LEUKOCYTE ANTIGEN;

ADULT; ALTERNATIVE RNA SPLICING; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DELIVERY; DISEASE SEVERITY; ENDOTHELIAL DYSFUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; GENETIC VARIABILITY; GESTATIONAL AGE; HUMAN; HUMAN TISSUE; IMMUNOLOCALIZATION; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PLACENTA; PREECLAMPSIA; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PUERPERIUM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; BLOOD; FRANCE; IMMUNOHISTOCHEMISTRY; METABOLISM; NONPARAMETRIC TEST; PREGNANCY;

ADULT; ANTIGENS, CD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FRANCE; HUMANS; IMMUNOHISTOCHEMISTRY; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; RECEPTORS, CELL SURFACE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STATISTICS, NONPARAMETRIC; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84858066284     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033475     Document Type: Article

References (36)

1. Sibai B, Dekker G, Kupferminc M, (2005) Pre-eclampsia. Lancet 365: 785-799.
2. Roberts JM, Gammill HS, (2005) Preeclampsia: recent insights. Hypertension 46: 1243-1249.
3. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, et al. (2006) Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 355: 992-1005.
4. Lam C, Lim KH, Karumanchi SA, (2005) Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension 46: 1077-1085.
5. Tsatsaris V, Goffin F, Munaut C, Brichant JF, Pignon MR, et al. (2003) Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab 88: 5555-5563.
6. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, et al. (2006) Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 12: 642-649.
7. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L, (2006) VEGF receptor signalling- in control of vascular function. Nat Rev Mol Cell Biol 7: 359-371.
8. Takahashi H, Shibuya M, (2005) The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond) 109: 227-241.
9. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH, (1994) Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 269: 26988-26995.
10. Gille H, Kowalski J, Li B, LeCouter J, Moffat B, et al. (2001) Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem 276: 3222-3230.
11. Clark DE, Smith SK, Sharkey AM, Charnock-Jones DS, (1996) Localization of VEGF and expression of its receptors flt and KDR in human placenta throughout pregnancy. Hum Reprod 11: 1090-1098.
12. Ahmad S, Ahmed A, (2004) Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res 95: 884-891.
13. Maynard SE, Min JY, Merchan J, Lim KH, Li J, et al. (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111: 649-658.
14. Gu Y, Lewis DF, Wang Y, (2008) Placental productions and expressions of soluble endoglin, soluble fms-like tyrosine kinase receptor-1, and placental growth factor in normal and preeclamptic pregnancies. J Clin Endocrinol Metab 93: 260-266.
15. Caniggia I, Grisaru-Gravnosky S, Kuliszewsky M, Post M, Lye SJ, (1999) Inhibition of TGF-beta 3 restores the invasive capability of extravillous trophoblasts in preeclamptic pregnancies. J Clin Invest 103: 1641-1650.
16. Lim JH, Kim SY, Park SY, Yang JH, Kim MY, et al. (2008) Effective prediction of preeclampsia by a combined ratio of angiogenesis-related factors. Obstet Gynecol 111: 1403-1409.
17. Maynard S, Epstein FH, Karumanchi SA, (2008) Preeclampsia and angiogenic imbalance. Annu Rev Med 59: 61-78.
18. Lohela M, Bry M, Tammela T, Alitalo K, (2009) VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 21: 154-165.
19. Ebos JM, Bocci G, Man S, Thorpe PE, Hicklin DJ, et al. (2004) A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. Mol Cancer Res 2: 315-326.
20. Ebos JM, Lee CR, Bogdanovic E, Alami J, Van Slyke P, et al. (2008) Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth. Cancer Res 68: 521-529.
21. Swendeman S, Mendelson K, Weskamp G, Horiuchi K, Deutsch U, et al. (2008) VEGF-A stimulates ADAM17-dependent shedding of VEGFR2 and crosstalk between VEGFR2 and ERK signaling. Circ Res 103: 916-918.
22. Albuquerque RJ, Hayashi T, Cho WG, Kleinman ME, Dridi S, et al. (2009) Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. Nat Med 15: 1023-1030.
23. Helske S, Vuorela P, Carpen O, Hornig C, Weich H, et al. (2001) Expression of vascular endothelial growth factor receptors 1, 2 and 3 in placentas from normal and complicated pregnancies. Mol Hum Reprod 7: 205-210.
24. Reddy A, Suri S, Sargent IL, Redman CW, Muttukrishna S, (2009) Maternal circulating levels of activin A, inhibin A, sFlt-1 and endoglin at parturition in normal pregnancy and pre-eclampsia. PLoS One 4: e4453.
25. Wallner W, Sengenberger R, Strick R, Strissel PL, Meurer B, et al. (2007) Angiogenic growth factors in maternal and fetal serum in pregnancies complicated by intrauterine growth restriction. Clin Sci (Lond) 112: 51-57.
26. Chaiworapongsa T, Romero R, Gotsch F, Espinoza J, Nien JK, et al. (2008) Low maternal concentrations of soluble vascular endothelial growth factor receptor-2 in preeclampsia and small for gestational age. J Matern Fetal Neonatal Med 21: 41-52.
27. Tripathi R, Rath G, Ralhan R, Saxena S, Salhan S, (2009) Soluble and membranous vascular endothelial growth factor receptor-2 in pregnancies complicated by pre-eclampsia. Yonsei Med J 50: 656-666.
28. Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, et al. (2000) Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 95: 952-958.
29. Zhou Y, McMaster M, Woo K, Janatpour M, Perry J, et al. (2002) Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol 160: 1405-1423.
30. George M, Rainey MA, Naramura M, Foster KW, Holzapfel MS, et al. (2011) Renal thrombotic microangiopathy in mice with combined deletion of endocytic recycling regulators EHD3 and EHD4. PLoS One 6: e17838.
31. Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, et al. (1989) Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 161: 1200.
32. Powe CE, Levine RJ, Karumanchi SA, (2011) Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation 123: 2856-2869.
33. Agatisa PK, Ness RB, Roberts JM, Costantino JP, Kuller LH, et al. (2004) Impairment of endothelial function in women with a history of preeclampsia: an indicator of cardiovascular risk. American journal of physiology Heart and circulatory physiology 286: H1389-1393.
34. Grundmann M, Woywodt A, Kirsch T, Hollwitz B, Oehler K, et al. (2008) Circulating endothelial cells: a marker of vascular damage in patients with preeclampsia. American Journal of Obstetrics and Gynecology 198: 317 e311-315.
35. Hladunewich MA, Myers BD, Derby GC, Blouch KL, Druzin ML, et al. (2008) Course of preeclamptic glomerular injury after delivery. Am J Physiol Renal Physiol 294: F614-620.
36. Makkonen N, Heinonen S, Hongisto T, Penttila I, Kirkinen P, (2002) Normalization of vasoactive changes in preeclampsia precedes clinical recovery. Hypertension in pregnancy 21: 51-64.